Gregory Seal
Shreveport, LANPI 1811947153
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Alkermes, Inc. at 30.7% of the total.
Across 106 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$706
- Neurocrine Biosciences, Inc.$499
- Otsuka America Pharmaceutical, Inc.$448
- Johnson & Johnson$212
- Lundbeck LLC$150
- AbbVie$129
- plus $156 from 2 others
Across 192 payments — averaging $5055.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$720K
- Sunovion Pharmaceuticals Inc.$122K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$77K
- Roche TCRC, Inc.$47K
- H. Lundbeck A S$4K
What the payments were for
- Food & beverage$2,295100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 30 | $706 |
| Neurocrine Biosciences, Inc. | 30 | $499 |
| Otsuka America Pharmaceutical, Inc. | 13 | $448 |
| Johnson & Johnson | 8 | $212 |
| Lundbeck LLC | 10 | $150 |
| AbbVie | 3 | $129 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $96 |
| Teva Pharmaceuticals USA, Inc. | 5 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$907
- ARISTADA INITIO$227
- VRAYLAR$125
- INVEGA SUSTENNA$125
- INVEGA TRINZA$125
- ABILIFY MAINTENA$125
- REXULTI$124
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.